qIRV + bivalent BNT162b2 (dose level combination 1) for Coronavirus

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
North Alabama Research Center, Athens, ALCoronavirus+5 Morebivalent BNT162b2 (original/Omi BA.4/BA.5) - Biological
Eligibility
18 - 64
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study the safety and effectiveness of 3 doses of a quadrivalent and bivalent flu vaccine.

Eligible Conditions
  • Coronavirus
  • Flu

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

7 Primary · 9 Secondary · Reporting Duration: At 1-, 4-, and 8 weeks after vaccination

1 week after vaccination
Percentage of participants with abnormal troponin I laboratory values
Percentage of participants with new ECG abnormalities
2 days after vaccination
Electrocardiogram
At 1-, 4-, 8-weeks after vaccination
Hemagglutination Inhibition Tests
Hemagglutination Inhibition Tests
Week 8
GMFRs of SARS-CoV-2 Omicron (BA.4/BA.5)-neutralizing titers and SARS-CoV-2 reference-strain-neutralizing titers
Neutralization Tests
Week 8
Percentage of participants with seroresponse based on SARS-CoV-2 Omicron (BA.4/BA.5)-neutralizing titers and SARS-CoV-2 reference-strain-neutralizing titers
At 1-, 4-, and 8-weeks after vaccination
Hemagglutination Inhibition Tests
At baseline, and 1-, 4-, and 8-weeks after vaccination
Hemagglutination Inhibition Tests
Geometric Mean Titers (GMTs) of hemagglutination inhibition (HAI) titers
Before vaccination and at 1-, 4-, 8-weeks after vaccination
Percentage of participants with HAI titers ≥ 1:40 for each strain
Week 4
Percentage of participants reporting adverse events
Month 6
Percentage of participants reporting serious adverse events
Day 7
Percentage of participants reporting local reactions
Percentage of participants reporting systemic events

Trial Safety

Trial Design

6 Treatment Groups

qIRV + bivalent BNT162b2 (dose level combination 1)
1 of 6
qIRV + bivalent BNT162b2 (dose level combination 2)
1 of 6
qIRV + bivalent BNT162b2 (dose level combination 3)
1 of 6
qIRV (dose level 1)
1 of 6
qIRV (dose level 2)
1 of 6
bivalent BNT162b2 (dose level 1) + QIV
1 of 6

Experimental Treatment

360 Total Participants · 6 Treatment Groups

Primary Treatment: qIRV + bivalent BNT162b2 (dose level combination 1) · No Placebo Group · Phase 1

qIRV + bivalent BNT162b2 (dose level combination 1)Experimental Group · 2 Interventions: bivalent BNT162b2 (original/Omi BA.4/BA.5), qIRV (22/23) · Intervention Types: Biological, Biological
qIRV + bivalent BNT162b2 (dose level combination 2)Experimental Group · 2 Interventions: bivalent BNT162b2 (original/Omi BA.4/BA.5), qIRV (22/23) · Intervention Types: Biological, Biological
qIRV + bivalent BNT162b2 (dose level combination 3)Experimental Group · 2 Interventions: bivalent BNT162b2 (original/Omi BA.4/BA.5), qIRV (22/23) · Intervention Types: Biological, Biological
qIRV (dose level 1)
Biological
Experimental Group · 1 Intervention: qIRV (22/23) · Intervention Types: Biological
qIRV (dose level 2)
Biological
Experimental Group · 1 Intervention: qIRV (22/23) · Intervention Types: Biological
bivalent BNT162b2 (dose level 1) + QIVExperimental Group · 2 Interventions: bivalent BNT162b2 (original/Omi BA.4/BA.5), QIV · Intervention Types: Biological, Biological
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
QIV
2018
Completed Phase 3
~2370

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: at 1-, 4-, and 8 weeks after vaccination

Who is running the clinical trial?

PfizerIndustry Sponsor
4,352 Previous Clinical Trials
7,171,544 Total Patients Enrolled
BioNTech SELead Sponsor
51 Previous Clinical Trials
91,772 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,307 Previous Clinical Trials
4,836,107 Total Patients Enrolled

Eligibility Criteria

Age 18 - 64 · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Are applicants aged 80 or younger being admitted into this research project?

"This clinical trial requires that participants be no older than 64 years and at least 18 for enrollment." - Anonymous Online Contributor

Unverified Answer

How secure is dose level 1 of qIRV for humans?

"Due to the nascent nature of this trial, qIRV (dose level 1) received a score of one for safety. This rating is based on limited data indicating efficacy and safety." - Anonymous Online Contributor

Unverified Answer

How many health care facilities are conducting this experiment?

"The 19 sites currently running this study include The Heart Center in Orange, the Orange County Heart Institute in Tustin and the Orange County Research Center in Fort Lauderdale. Additionally, there are 16 other locations where research is being conducted." - Anonymous Online Contributor

Unverified Answer

How many participants are taking part in this clinical research?

"In order to achieve the desired number of participants, 180 people that match the eligibility requirements must be recruited. Potential candidates can sign up at The Heart Center in Orange, California or Orange County Heart Institute located in Tustin, Florida." - Anonymous Online Contributor

Unverified Answer

How many participants are still needed for this clinical trial?

"Indeed, according to information available on clinicaltrials.gov, this medical trial is presently recruiting patients. It was first uploaded to the website on October 28th 2022 and has been updated as recently as December 22nd 2022. The study aims to enroll 180 participants from 19 different sites across the country." - Anonymous Online Contributor

Unverified Answer

What are the primary aims of this clinical experiment?

"This clinical trial, to be executed over one week with final assessment after vaccination, aims to evaluate the percentage of participants with newly-acquired ECG abnormalities. Additionally, it seeks to measure HAI titers ≥ 1:40 for each strain at a central laboratory and determine SARS-CoV-2 Omicron (BA.4/BA.5)-neutralizing titers and SARS-CoV-2 reference-strain neutralizing GMFRs via seroconversion tests conducted in the same laboratory setting." - Anonymous Online Contributor

Unverified Answer

What are the eligibility requirements for participating in this clinical experiment?

"This clinical trial seeks 180 individuals aged 18-64 suffering from Covid19. In order to be eligible, applicants must demonstrate the capacity for informed consent, identify as male or female, comply with study visits and procedurers, have a healthy medical history verified by physical examination (if necessary), and have received 3 prior doses of BNT162b2 in the last 365 days preceding their first visit." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.